Diabetes Clinical Trials in Sacramento
View 40 new treatments for Diabetes in Sacramento, CA, and nearby areas, such as Elk Grove, Fairfield, Roseville and Vacaville. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Tirzepatide for Type 2 Diabetes and Obesity
Eli Lilly Clinic, Sacramento + 1 more
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.Show More
Verified
Recruiting
Phase 2
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Faricimab for Diabetic Macular Edema
Research Clinic, Sacramento + 1 more
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Dr. Varun Chaudhary, MD, FRCS(C)
Principal Investigator
Tirzepatide for Type 2 Diabetes
Eli Lilly Clinic, Lincoln + 1 more
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Rifampin for Osteomyelitis in Diabetics
Research Clinic, Sacramento + 1 more
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Mary T Bessesen, MD
Study Chair
Faricimab for Diabetic Macular Edema
Genentech Clinic, Sacramento + 1 more
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Clinical Trials
Study Director
Ranibizumab PDS Implant for Diabetic Retinopathy
Hoffmann-La Roche Clinic, Sacramento + 1 more
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator ArmShow More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Trials
Study Director
New Antibiotics vs Linezolid for Diabetic Foot Infections
MicuRx Clinic, Mather + 1 more
This trial tests a new antibiotic called contezolid, given either through an injection or as a pill, in adults with moderate or severe diabetic foot infections. The antibiotic works by stopping the bacteria from growing.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Semaglutide for Diabetic Eye Disease
Novo Nordisk Clinic, Sacramento + 2 more
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Clinical Reporting Anchor and Disclosure (1452)
Study Director
Aflibercept for Age-Related Macular Degeneration and Diabetic Macular Edema
Regeneron Clinic, Sacramento + 1 more
This study is researching an experimental drug called aflibercept 8 mg, referred to as "study drug". The study is focused on participants with nAMD and DME that have been previously treated with anti-vascular endothelial growth factor (anti-VEGF) medications. The aim of the study is to see how safe and effective aflibercept 8 mg injections are when given as frequently as every 4 weeks. The study is also looking at what side effects may happen from taking the study drug.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Clinical Trial Management
Study Director
Tirzepatide for Pediatric Type 2 Diabetes
Eli Lilly Clinic, Sacramento + 1 more
This trial is testing tirzepatide, a medication that helps control blood sugar levels, in children and teenagers with type 2 diabetes. These participants are already taking other diabetes medications like metformin or basal insulin. Tirzepatide works by helping the body use insulin more effectively and reducing sugar production in the liver. Tirzepatide is a new medication being tested for its effectiveness and safety in people with type 2 diabetes.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
1-877-CTLilly (1877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 5
Frequently Asked Questions
Explore related conditions